ALDXAldeyra Therapeutics Inc
ALDX
Aldeyra Therapeutics Inc8,230
Mkt Cap
$319.46MVolume
2.23M52W High
$7.2052W Low
$1.14PE Ratio
-7.27ALDX Fundamentals
Price
$5.25Prev Close
$5.31Open
$5.3850D MA
$5.09Beta
2.75Avg. Volume
709,263.53EPS (Annual)
-$0.9389P/B
6.41Rev/Employee
$0.00Aldeyra Therapeutics Target of Unusually Large Options Trading (NASDAQ:ALDX)
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Get Free Report) saw some unusual options trading activity on Tuesday. Investors bought 12,807 call options on the stock. This is an increase of 1,592...
MarketBeat·1d ago
683 Capital Management LLC Has $4.14 Million Stake in Aldeyra Therapeutics, Inc. $ALDX
683 Capital Management LLC grew its position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 126.9% during the second quarter, according to the company in its most recent 13F filing with...
MarketBeat·5d ago
Aldeyra Therapeutics, Inc. $ALDX Shares Sold by Kennedy Capital Management LLC
Kennedy Capital Management LLC lessened its position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 44.3% in the second quarter, according to the company in its most recent Form 13F...
MarketBeat·11d ago
Kennondale Capital Management LLC Sells 94,551 Shares of Aldeyra Therapeutics, Inc. $ALDX
Kennondale Capital Management LLC trimmed its holdings in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 62.5% in the second quarter, according to its most recent disclosure with the...
MarketBeat·21d ago
Savant Capital LLC Makes New $552,000 Investment in Aldeyra Therapeutics, Inc. $ALDX
Savant Capital LLC bought a new position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission...
MarketBeat·1mo ago
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at...
Business Wire·1mo ago
Aldeyra Therapeutics (NASDAQ:ALDX) Given Buy Rating at BTIG Research
BTIG Research reissued a "buy" rating and issued a $9.00 price target on shares of Aldeyra Therapeutics in a report on Monday...
MarketBeat·1mo ago
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced...
Business Wire·1mo ago
Aldeyra Therapeutics (NASDAQ:ALDX) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS
Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the...
MarketBeat·1mo ago
<
1
2
...
>